ABSTRACT
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with varied clinical manifestations and severe organ damage. 1 SLE is a heterogenic disease where T helper 2 (Th2) is suggested to play an important role in loss of immune tolerance and increased antigenic load with defective B-cell suppression. 2 Yet, elevation of cytokines related to Th1 and Th2 have been demonstrated in both animal and human models. 3 Lupus nephritis (LN) is a common, serious clinical feature of SLE that affects about one third of lupus patients. 4 Patients with LN have increased risk of progressive deterioration of kidney function as well as increased mortality rates. 5 The pathogenesis of LN is mostly attributed to glomerular deposition of immune complexes and cytokine imbalance. 6 Experimental models have shown the important role of Th1 cytokines in the development and progression of LN, where interleukin-12 (IL-12) and IL-18 were found in the glomeruli of human and animal models of LN. 7, 8 Interleukin-18 is a unique pro-inflammatory cytokine which is a key player in many inflammatory diseases. It strongly induces interferon-gamma Interleukin-18 as a Biomarker of Subclinical Lupus Nephritis (IFN-g) as well as promoting the production of other inflammatory mediators, such as tumor necrosis factor-a, and granulocyte macrophage colony stimulating factor (GM-CSF). 9 Several studies have shown that IL-18 was involved in initiation and progression of many primary and secondary kidney diseases. [10] [11] [12] In lupus patients, IL-18 has been implicated in the pathogenesis, activity and determination of severity of renal involvement. 13, 14 In murine models, overexpression of IL-18 receptor accessory chain on lymphocyte was demonstrated and this led to mounting of IFN-g secretion. Moreover, a relationship between tubular IL-18 expression and renal disease activity has been demonstrated. 13, 15 Tucci et al. 16 in 2008 demonstrated decrease in peripheral plasmacytoid dendritic cells (DCs), which expressed IL-18 receptor, in patients with LN and they suggested that the high level of expression of IL-18 receptor by peripheral plasmacytoid DCs helps the DCs to relocate within glomeruli under IL-18 stimulation and promote renal damage. Furthermore, Hatef et al. 17 in 2013 showed a correlation between IL-18 and serum Fas in patients with LN being highly significant in patients with severe SLE than those with milder disease. In addition, the therapy targeted to IL-18 was found to protect mice from LN. 18 Patients with LN may experience similar clinical manifestations despite having different degrees of renal involvement. Furthermore, patients with moderate levels of proteinurea (>1000 mg/24 h) might have significant renal involvement (Class III, IV or V LN). That is why renal biopsy in SLE is needed for early and accurate diagnosis of LN and hence early planning of treatment for better patients outcome. 19, 20 Yet, renal biopsy has its limitations and contraindications. That is why new biomarkers are needed to improve the diagnostic accuracy and sensitivity of lupus renal disease, monitoring of treatment response. 21 In this study, we investigated the relationship between serum IL-18 and its renal expression with histological classification of LN in patients with insignificant proteinuria, and evaluate serum IL-18 as a biomarker of subclinical renal involvement in lupus patients.
PATIENTS AND METHODS
This cross sectional, case-control, and observational study was conducted on 40 SLE patients (5 males, 35 females; mean age 26.3±7.9 years; range 16 to 52 years) with proteinuria less than 0.5 g/24 hours, recruited between October 2011 and December 2012. Patients were diagnosed according to the Updated of the 1982 American College of Rheumatology revised criteria for diagnosis of SLE. 22 The study also included 20 apparently healthy controls (2 males, 18 females, mean age 25.5±6.3 years; range 16 to 49 years). Patients with other rheumatic diseases and nephritis due to other causes were excluded as well as patients with proteinuria >500 mg/24hrs and patients with coexisting causes of renal involvement. All patients were subjected to full history taking. Thorough clinical examination was performed to each patient with special emphasis on symptoms and signs of renal involvement, assessment of the disease activity according to the University of Toronto Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). 23 All patients were on prednisone (15-25 mg/day), hydroxychloroquine (400 mg/day), and azathioprine (100-150 mg/day). All participants gave written informed consents to participate after receiving full explanation of the study, which was approved by our local ethics committee.
Venous blood (8 mL) was withdrawn from each patient where, 5 mL were placed in EDTA tube for performing complete blood count and erythrocyte sedimentation rate (ESR), and 3 mL of blood were collected in plain vacutainers for analysis of antinuclear antibodies and anti-double stranded DNA (anti-dsDNA). Serum samples were stored at -20 °C until time of assay. Complete blood count was done using Coulter counter (T660) (Coulter Electronics Inc., USA), ESR was done by the Westergren method. Antinuclear antibodies and anti-dsDNA antibodies were analyzed using indirect immunofluorescence assay using IMMCO Diagnostics (IMMCO Diagnostics, Inc., NY, USA), (antinuclear antibodies on Hep-2 substrate and anti-dsDNA on crithidialuciliae substrate). Serum complement level assessment (C3 and C4) was performed by Nephelometry (Minineph human Ig kit, Binding site Ltd, Birmingham, UK). Renal function tests including serum creatinine, blood urea, creatinine clearance and routine microscopic urine analysis for presence of pyuria, hematuria and casts were done. Twenty-four hours urine was collected to assay protein. Liver and kidney function tests were conducted using Synchron CX9 (Beckman instrument Inc., Brea, California, USA).
Quantative analysis of IL-18 was performed using a commercially available enzyme-linked Immunohistochemical staining was performed at room temperature using immunostainer (Shandon Sequenza Immunostainer). Formaldehyde fixed paraffinembedded serial sections of renal biopsies were cut at 4-μm thickness and mounted onto Superfrost plus slides. Sections were dewaxed and hydrated in graded ethanol prior to antigen retrieval by microwaving in 0.01M citrate buffer (pH 6.0) for 6 minutes. Endogenous peroxidase activity was inactivated with 3% H 2 O 2 in methanol for 20 minutes. Sections were treated with 5% goat serum in Tris-buffered saline to block nonspecific binding. Goat anti-human IL-18 (R&D Systems, Abingdon, United Kingdom) was added at a dilution of 1:200 (final concentration of 0.5 mug/mL) and sections were incubated overnight at 4 °C. The biotinylated conjugate and streptavidin peroxidase were applied for 15 minutes, and diaminobenzidine chromogen was used as a peroxidase substrate complex (all from DAKO labelled streptavidin biotin + kit peroxidase, DAKO Copenhagen, Denmark). Tissue sections were then counterstained with hematoxylin for 10 seconds, dried and mounted with aqueous mounting medium (DAKO Copenhagen, Denmark). Intrinsic positive controls for immunoreactivity in each section were IL-18 stained cells in lymphoid follicles. Each series of sections contained negative controls without primary antibodies. In addition, a control using immunoglobulin G from non-immunized goats (R&D systems) at the same concentration as that of anti-IL-18 immunoglobulin G was carried out in a number of tissue sections that excluded nonspecific binding. The renal tissues 
Statistical analysis
Statistical analysis was performed using SPSS for Windows version 10.0 software program (SPSS Inc., Chicago, IL, USA). Descriptive statistics were expressed in the form of mean, standard deviation, minimum, maximum, and range of numerical data as well as frequency and percentage of non-numerical data. Student's t test was used to test the difference in mean values of continuous variables, and Chi-square test to compare two groups regarding non-numerical variables. Correlation (Pearson correlation coefficient r) assessing strength and direction of the linear relationship between two variables was shown, and one-way ANOVA test (F) was used to test the difference between more than two means. Diagnostic validity tests were calculated.
RESULTS
Descriptive laboratory and clinical data of SLE patients are displayed in Tables 1 and 2 . SLE patients had a significantly higher serum IL-18 level (612.4±169.6 pg/mL) than controls (209.3±92.3 pg/mL) (z= -6.234, p<0.01). Serum IL-18 showed significant positive correlation with serum creatinine and blood urea nitrogen (BUN) of our patients (r=0.462, p=0.003 and r=0.428, p=0.006, respectively), while it did not correlate significantly with the disease activity assessed by the SLEDAI (r=0.004, p>0.01) nor with any of the other laboratory data of the patients nor with the dose of prednisone or azathioprine.
Histopathological examination of the 40 renal tissue sections included in our study showed that two cases (5%) were class I, 12 cases (30%) were class II, 16 cases (40%) were class III, nine cases (22.5%) were class IV, while class V was only represented by one case (2.5%). The mean values for the activity and chronicity indices were as follows; 2.42, 3.19 and 4.44 mean activity score for classes II, III, IV, respectively and 2.92, 3.11 and 2.5 mean chronicity score for classes II, III, IV, respectively. Serum IL-18 showed significant positive correlation with the activity index of the renal biopsies (r=0.534, p<0.001) ( Figure 5 ). It also demonstrated significant increase among the different classes of glomerulonephritis (Table 3 and Figure 6 ).
Interleukin-18 immunoexpression is designated as brown granular cytoplasmic immunostaining. IL-18 immunoreactivity was observed in the epithelium of renal tubules in 75% of class II cases and 100% of classes III, IV and V. IL-18 immunostaining also showed glomerular expression in 50% of class II cases, 62.5% of class III cases and 100% of both classes IV and V (Figures 7-9 ). Meanwhile, immunostaining was neither glomerular nor tubular in class I. A highly To confirm the role of IL-18 in detecting the severity of renal involvement as determined by renal biopsy, patients were divided into two groups according to the 2003 classification of LN. Group 1 with class I and II renal glomerulonephritis showed significantly lower serum IL-18 than group 2 of SLE patients with class III, IV and V (461.6±96.3 pg/m; and 693.7±142.6 pg/mL, respectively; p=0) ( Figure 10) . None of the renal function tests measured in this study (serum creatinine, BUN, creatinine clearance and protein-creatinine ratio) showed significant difference among these two groups of SLE patients.
DISCUSSION
Systemic lupus erythematosis is a systemic autoimmune disease with multi-organ affection and diversity of clinical presentations as well as unpredictable course. 28 Kidney disease is common in course of SLE and may occur at any time, presenting a central and serious complication with glomerulonephritis as a major cause of morbidity and mortality in patients with SLE. 29, 30 Pathogenesis of LN involves many players. One of these players is overproduction of Th1 cytokines, among which is IL-18.
In the current work, we studied the serum level and renal expression of IL-18 in lupus patients with insignificant proteinuria. Serum IL-18 was significantly higher in SLE patients than controls. This finding agrees with the results reported by other research groups. 1, 7, 14, [31] [32] [33] It showed significant positive correlation with serum creatinine and BUN. IL-18 being an important regulator of Th1 responses has a role in the pathogenesis of LN as it stimulates production of pro-inflammatory cytokines such as TNF-a and IL-1b in Th1 cells, and macrophages, upregulates chemokine production and expression of adhesion molecules, enhances perforin-and FasL-mediated cytotoxicity by NK and T cells, and induces the release of matrix metalloproteinases, which contributes to the inflammatory reaction and subsequent tissue damage. 14 In our study, IL-18 did not correlate significantly with the disease activity assessed by the SLEDAI nor with any of the other laboratory data of the patients. This was not in concordance with Migliorini et al.
14 who found that total and free serum IL-18 levels were higher in patients with active disease (with nephritis or active non-renal disease), while urinary levels of total and free IL-18 did not correlate with disease activity, nor with other reports. 31, 34, 35 This difference in reports could be due to the fact that non of our lupus patients had inactive disease and they all ranged from mild to severe activity with a mean SLEDAI of 13.7±4.3 which made it difficult to correlate the IL-18 level with the whole spectrum Unfortunately, similar clinical manifestations are observed among SLE patients in spite of different classes of LN, and considerable renal involvement (class III, IV, or V LN) can occur in SLE patients with insignificant proteinuria (<0.5 gm/24 hours). 36, 37 Histopathological examination of the 40 renal biopsies of patients included in our study showed that two patients (5%) had class I, 12 (30%) had class II, 16 (40%) had class III, nine (22.5%) had class IV and only one patient (2.5%) had class V LN.
Local production of IL-18 has been reported to play an important role in driving the migration of dendritic cells to the kidney with attraction of more inflammatory cells and maintenance of kidney inflammation. 6, 38 Data from several studies suggested that up-regulation of IL-18 in animal models and humans, is associated with nephritic kidneys and related to the degree of renal inflammation. 33, 39 In our study, we found that serum levels of IL-18 showed significant increase among the different classes of glomerulonephritis, being higher in class IV and V LN than in class III and II LN. We have also demonstrated that serum IL-18 correlated significantly with the activity index of the renal biopsies.
Testing for serum IL-18 helped us to differentiate between milder (class I and II) severe (class III, IV and V) forms of LN where all renal functions tested showed no significant differences between all forms of LN.
As well, renal expression of IL-18 was valuable. IL-18 was present in the epithelium of renal tubules in 75% of class II cases and 100% of classes III, IV and V where it showed glomerular expression in 50% of class II cases, 62.5% of class III cases and 100% of both classes IV and V (Figures 7-9 ). These findings corroborate the findings of Faust et al., 13 who described marked expression of IL-18 in nephritic kidneys from Fas mice lpr that was not confined to interstitial or glomerular infiltrating mononuclear cells, but was also detected in tubular epithelial cells. They attributed elevated circulating levels of IL-18 in part to the local IL-18 production within the kidneys. Their further in vitro studies suggested that up regulation of renal IL-18 is a prerequisite for the local inflammatory cytokine cascade especially that the interaction between TNF and IL-18 might provide a positive-amplification loop that accelerates the auto-immune kidney disease. In addition to a possible role of IL-18 in the induction of apoptosis in tubular epithelial cells, 13 Shui et al. 40 also demonstrated IL-18 overexpression, associated with hyperplasia and apoptosis of mesangial cells in the glomeruli of lipopolysaccharid-accelerated LN mice. They suggested that local IL-18 in the nephritic kidneys could act like a paracrine cytokine to exacerbate glomerular inflammation and is probably involved in the apoptosis of the downstream tubular cells. The increased glomerular expression of IL-18 in established human LN was also reported by different groups. 7, 16, 33, 41 To our knowledge, we are the first group to report expression of IL-18 in renal tissue of subclinical LN.
The increased expression in renal tissue was accompanied by an increase in serum IL-18 that showed statistically significant difference among the different types of both glomerular and tubular expression (whether faint focal, focal or diffuse). These findings verify that serum IL-18 can successfully mirror the tissue affection in the kidneys rendering it a probable biomarker of early renal involvement in LN even in the absence of significant proteinuria.
In conclusion, IL-18 may play an important role in the pathogenesis of LN. Data present in this work showed that serum IL-18 reflects the extent of renal injury in lupus even in absence of significant proteinuria regardless of the level of disease activity; proposing its early role in pathogenesis of LN via both local and systemic sources. Thus, IL-18 can be used as a biomarker 
